BioCryst and the Pan-Canadian Pharmaceutical Alliance (PCPA) Successfully Complete Negotiations for ORLADEYO (Berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema Attacks
BlackRock Inc. Expands Stake in BioCryst Pharmaceuticals
Island Pharmaceuticals Signs Letteer of Intent to Acquire BioCryst's Antiviral Program
BioCryst Presents Results on HAE Treatment and Patient Care at Global Symposium
BioCryst Presents New ORLADEYO (Berotralstat) Data at 7th Bradykinin Symposium
Express News | BioCryst Appoints DR. Donald Fong Chief Medical Officer
Press Release: BioCryst Appoints Dr. Donald Fong Chief Medical Officer
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Large Institutional Owners Must Be Happy as Stock Continues to Impress, up 7.3% Over the Past Week
BioCryst to Present at Upcoming Investor Conferences
'Bottom-fishing' Ideas Within Piper Sandler's Universe of Stocks
Piper Lists Eight Defensive Biotechs to Face Market Volatility
Evercore Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $10
Evercore analyst Liisa Bayko maintains $BioCryst Pharmaceuticals(BCRX.US)$ with a buy rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success rate of 45.6%
BioCryst Pharmaceuticals | 10-Q: Q2 2024 Earnings Report
JMP Securities Maintains Market Outperform on BioCryst Pharma, Raises Price Target to $16
BioCryst Pharmaceuticals Is Maintained at Equal-Weight by Barclays
BioCryst Pharmaceuticals Price Target Raised to $7.00/Share From $6.00 by Barclays
A Quick Look at Today's Ratings for BioCryst Pharmaceuticals(BCRX.US), With a Forecast Between $10 to $30
On Aug 06, major Wall Street analysts update their ratings for $BioCryst Pharmaceuticals(BCRX.US)$, with price targets ranging from $10 to $30.Evercore analyst Liisa Bayko maintains with a buy rating,
BioCryst Pharmaceuticals: A Buy Rating Anchored on Orladeyo's Success and Expansion in Rare Disease Treatments
HC Wainwright & Co. Reiterates Buy on BioCryst Pharma, Maintains $30 Price Target